Chibaya, Loretah
Murphy, Katherine C. http://orcid.org/0000-0002-5962-9896
DeMarco, Kelly D.
Gopalan, Sneha
Liu, Haibo http://orcid.org/0000-0002-4213-2883
Parikh, Chaitanya N.
Lopez-Diaz, Yvette
Faulkner, Melissa
Li, Junhui http://orcid.org/0000-0003-3973-1700
Morris, John P. IV
Ho, Yu-jui
Chana, Sachliv K.
Simon, Janelle
Luan, Wei
Kulick, Amanda
de Stanchina, Elisa
Simin, Karl http://orcid.org/0000-0002-7431-0939
Zhu, Lihua Julie http://orcid.org/0000-0001-7416-0590
Fazzio, Thomas G.
Lowe, Scott W. http://orcid.org/0000-0002-5284-9650
Ruscetti, Marcus http://orcid.org/0000-0002-4394-2087
Article History
Received: 20 June 2022
Accepted: 5 April 2023
First Online: 4 May 2023
Competing interests
: S.W.L. is a founder and member of the scientific advisory board of Blueprint Medicines, Mirimus Inc., ORIC Pharmaceuticals, Senescea and Faeth Therapeutics, is on the scientific advisory board of PMV Pharmaceuticals, and is a consultant for Fate Therapeutics. M.R. is a consultant for Boehringer Ingelheim. L.C. and M.R. have filed a US patent application (US22/45163) related to this work. The remaining authors declare no competing interests.